{"id":"formulation-c-onabotulinumtoxina","safety":{"commonSideEffects":[{"rate":"null","effect":"Eyelid ptosis"},{"rate":"null","effect":"Diplopia"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Facial asymmetry"},{"rate":"null","effect":"Dry mouth"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Injection site pain"},{"rate":"null","effect":"Injection site erythema"},{"rate":"null","effect":"Injection site induration"},{"rate":"null","effect":"Injection site pruritus"}]},"_chembl":{"chemblId":"CHEMBL1201574","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking acetylcholine release, onabotulinumtoxinA reduces muscle spasms and contractions, providing relief for conditions such as blepharospasm and cervical dystonia. This mechanism is achieved through the inhibition of acetylcholine release at the neuromuscular junction.","oneSentence":"OnabotulinumtoxinA works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:32:40.529Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Blepharospasm"},{"name":"Cervical dystonia"},{"name":"Spasticity"},{"name":"Hemifacial spasm"},{"name":"Strabismus"},{"name":"Axillary hyperhidrosis"},{"name":"Severe primary axillary hyperhidrosis"},{"name":"Lateral ptosis"},{"name":"Severe glabellar lines"},{"name":"Upper limb spasticity"}]},"trialDetails":[{"nctId":"NCT05013424","phase":"PHASE2","title":"A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2021-09-01","conditions":"Glabellar Lines","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BOTOX"],"phase":"phase_2","status":"active","brandName":"Formulation C: OnabotulinumtoxinA","genericName":"Formulation C: OnabotulinumtoxinA","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OnabotulinumtoxinA works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction. Used for Blepharospasm, Cervical dystonia, Spasticity.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}